Navigation Links
The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
Date:1/24/2013

PHOENIX, Jan. 24, 2013 /PRNewswire/ -- The Arizona Chapter of The Leukemia & Lymphoma Society and Avella Specialty Pharmacy announce they will present a day of discussion about the latest advancements, trends and management of oral chemotherapy medications. The free event will take place on Feb. 9, from 10:30 a.m. to 2:30 p.m., at SkySong, the ASU Scottsdale Innovation Center, 1475 N. Scottsdale Road, Scottsdale.

Local hematology/oncology community members will provide in-depth presentations on oral chemotherapy drugs including current trends, compliance and medication management. The event will feature two breakout sessions – one for nurses wherein they can earn complimentary CE credits and the other track for cancer patients and their families – as well as a town hall-style session featuring several local experts.

"More than 35 percent of the 400 cancer drugs in the pipeline are oral chemotherapy drugs. They clearly are the wave of the future," stated John Musil , Pharm.D., founder and CEO of Avella. "However, with so many breakthroughs, it's difficult for patients to stay on top of all of them. Our partnership with The Leukemia & Lymphoma Society aligns with our mission of optimizing patient health by educating healthcare professionals and patients on these advancements. Our hope is to provide similar discussions throughout the year as there is a growing need for this type of education."

Healthcare professionals will learn about current oral chemotherapy drug trends, compliance and best practices on how to provide adequate patient surveillance and support. Eric Sredzinski , Pharm.D., AAHIVE, Pharmacy Program Director, ADAP at Avella will lead this session. Continuing education credit will be provided to nurses.

The patient breakout session will focus on the importance of adhering to oral chem
'/>"/>

SOURCE Avella Specialty Pharmacy
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
2. Burlington Coat Factory Completes Another Record Year of Supporting The Leukemia & Lymphoma Society in its Quest to Beat Cancer
3. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
4. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
5. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
6. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
7. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
8. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
9. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
10. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
11. Medical Devices 2013: A Frost & Sullivan Executive MindXchange- Sustaining the Vitality of the Industry and Your Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical ... announced that it has entered into a $20 million ... HTGC).  The loan agreement includes both a $5 million ... term loan. Proceeds are expected to be ...
... Aug. 8, 2011 Global Health Ventures Inc. ... on sublingual drug delivery announced today that their August ... and CEO, is available for on-demand viewing. ... watch event now" button. Their presentation will ...
Cached Medicine Technology:NeurogesX, Inc. Secures $20 Million Debt Facility 2NeurogesX, Inc. Secures $20 Million Debt Facility 3NeurogesX, Inc. Secures $20 Million Debt Facility 4Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... metastasis , , MONDAY, March 3 (HealthDay News) -- A ... stem cells can inhibit the growth and spread of ... by researchers at Northwestern University in Chicago. , The ... Proceedings of the National Academy of Sciences , ...
... Ronnie B. Martin, DO,FACOFP-dist. of Parker, Colo., will ... College of Osteopathic Family Physicians during the 45th ... in Denver, Colo., For more than 50 ... health and welfare of patients served by osteopathic,family ...
... searched for a novel cancer drug that activates a ... drug that kills the cancer without causing damage to ... at the University of Michigan Comprehensive Cancer Center have ... cell cultures at inhibiting the interaction between this protein, ...
... Tied Directly ... to Increased Production Efficiency, NEW ORLEANS, March 3 ... couldn,t previously be,solved, Waters Corporation (NYSE: WAT ) today ... Chemistry and,Applied Spectroscopy, March 2 - 6, 2008 in New ...
... 2008, AT 5 P.M. EST) A research team from ... University and Hospital in Taiwan have described for the first ... CAPON or NOS1AP, can disrupt normal heart rhythm. Until recently, ... or playing a role in heart function. , The study, ...
... 3, 2008) New high-throughput methods are revolutionizing ... of Cold Spring Harbor Protocols ( www.cshprotocols.org/TOCs/toc3_08.dtl ... turn genes on and off. Both methods are ... Spring Harbor Protocols ( www.cshprotocols.org ). , Our ...
Cached Medicine News:Health News:Embryonic Stem Cell Protein Inhibits Melanoma 2Health News:Ronnie B. Martin, DO, FACOFP-dist. to be Inaugurated as the 55th President of the ACOFP (2008-2009) 2Health News:Ronnie B. Martin, DO, FACOFP-dist. to be Inaugurated as the 55th President of the ACOFP (2008-2009) 3Health News:U-M researchers ID promising new cancer drug 2Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 2Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 3Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 4Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 5Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 6Health News:Researchers describe mechanisms by which capon gene causes heart rhythm disturbances 2Health News:Cold Spring Harbor Protocols features high-throughput methods for analyzing gene activity 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: